Clinical trial · Interventional
The Efficacy and Tolerability of Modafinil for Fatigue and Daytime Sleepiness in Cancer Patients: Preliminary Study
NCT02385656CI-TRIAL-00017110unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Open-pilot study for the efficacy and tolerability of modafinil on the fatigue and somnolence in cancer-patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Fatigue | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Modafinil | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Intervention group
- description
- Subjects who take modafinil for cancer-related fatigue for 4 weeks.
- interventionNames
- Drug: Modafinil
Primary outcomes (1)
- measure
- severity of fatigue (Brief Fatigue Inventory)
- timeFrame
- 4 weeks
- description
- Brief Fatigue Inventory
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * solid cancer patient * age of 20-65 years old * subjects who scored =4 or \>4 on the Brief Fatigue Inventory * subjects with informed consent Exclusion Criteria: * metastatic cancer(stage IV) * with psychotic symptoms such as delusion and hallucination or with suicidal risk * with delirium or dementia * current medication of cognitive enhancer or psychostimulant uncontrolled medical illness * current medications that are contraindicated or not recommended for co-administration with modafinil
References
Publications (0)
Data not yet available
No reference posted for this study.